Vaxcyte Shares Are Soaring: Here's Why

Loading...
Loading...

Vaxcyte Inc PCVX shares are trading higher Monday after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24.

VAX-24 is the company's investigational 24-valent pneumococcal conjugate vaccine. In the study, VAX-24 met the primary safety and tolerability objectives, demonstrating a safety profile similar to Prevnar 20 for all doses studied.

"The study results demonstrate that VAX-24 has the potential to provide broader coverage and better immune responses relative to the standard-of-care. We believe this presents an opportunity to set a new bar for immunogenicity standards for pneumococcal vaccines," said Grant Pickering, co-founder and CEO of Vaxcyte.

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases.

See Also: US Stocks Could Continue Last Week's Momentum As Nasdaq, S&P 500 Futures Surge Ahead Of Tech-Heavy Earnings Week

PCVX Price Action: Vaxcyte is making new 52-week highs on Monday.

The stock was up 77.4% at $36.50 at time of publication, according to Benzinga Pro.

Photo: Konstantin Kolosov from Pixabay.

Market News and Data brought to you by Benzinga APIs
Posted In: Small CapMoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...